- Home
- GLBE vs KNSA Comparison
GLBE vs KNSA Comparison
Compare GLBE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLBE | KNSA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.9B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GLBE | KNSA |
|---|---|---|
| Price | $39.95 | $78.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $47.08 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.3M | 467.9K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $31.78 | $37.48 |
| Revenue Next Year | $24.45 | $17.87 |
| P/E Ratio | ★ $89.26 | $295.56 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $26.85 | $33.54 |
| 52 Week High | $43.99 | $82.94 |
Technical Indicators
Market Signals| Indicator | GLBE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 59.00 |
| Support Level | $37.78 | $44.95 |
| Resistance Level | $41.77 | $82.25 |
| Average True Range (ATR) | 1.43 | 2.23 |
| MACD | -0.46 | -0.56 |
| Stochastic Oscillator | 5.78 | 56.73 |
Price Performance
Historical ComparisonAbout GLBE Global-E Online Ltd.
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from, and to, anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.